Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Journal of Clinical Oncology · 20.08.2024 · 42 (24) · 2918-2927
DOI: 10.1200/jco.23.02736 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2024. Verfasst von Akihito Kawazoe und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Phenylurea Compounds, Colorectal Neoplasms, Quinolines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination with pembrolizumab improves outcomes compared with standard of care (SOC) in previously treated mismatch repair proficient or not microsatellite instability high (pMMR or not MSI-H) mCRC. METHODS In this international, multicenter, randomized, controlled, open-label, phase III study, eligible patients age 18 years and older with unresectable, pMMR or not MSI-H mCRC, that had progressed on or after, or could not tolerate, standard treatment, were randomly assigned 1:1 to lenvatinib 20 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks or investigator's choice of regorafenib or trifluridine/tipiracil (SOC). Randomization was stratified by presence or absence of liver metastases. The primary end point was overall survival (OS). LEAP-017 is registered at ClinicalTrials.gov ( NCT04776148 ), and has completed recruitment. RESULTS Between April 8, 2021, and December 21, 2021, 480 patients were randomly assigned to lenvatinib plus pembrolizumab (n = 241) or SOC (n = 239). At final analysis (median follow-up of 18.6 months [IQR, 3.9]), median OS with lenvatinib plus pembrolizumab versus SOC was 9.8 versus 9.3 months (hazard ratio [HR], 0.83 [95% CI, 0.68 to 1.02]; P = .0379; prespecified threshold P = .0214). Grade ≥3 treatment-related adverse events occurred in 58.4% (lenvatinib plus pembrolizumab) versus 42.1% (SOC) of patients. Two participants died due to treatment-related adverse events, both in the lenvatinib plus pembrolizumab arm. CONCLUSION In patients with pMMR or not MSI-H mCRC that had progressed on previous therapy, there was no statistically significant improvement in OS after lenvatinib plus pembrolizumab treatment versus SOC. No new safety signals were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangdong, China.
- Medical Oncology Service, Hospital G. U. Gregorio Marañón, IiSGM, Universidad Complutense, Madrid, Spain.
- Rambam Health Care Campus-Oncology, Haifa, Israel.
- Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
- National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
ORCID-Profile: Akihito Kawazoe, Rui-Hua Xu, Pilar García-Alfonso, Ardaman Shergill, Mahmut Gumus, Sebastian Stintzing, Tae Won Kim, Kai Keen Shiu, Andrey Lebedinets, Volker Heinemann, Takayuki Yoshino, Elena Elez
Zitieren
APA
Kawazoe, A., Xu, R. H., García-Alfonso, P., Passhak, M., Teng, H. W., Shergill, A., Gumus, M., Qvortrup, C., Stintzing, S., Towns, K., Kim, T. W., Shiu, K. K., Cundom, J., Ananda, S., Lebedinets, A., Fu, R., Jain, R., Adelberg, D., Heinemann, V., …, & LEAP-017 Investigators (2024). Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of Clinical Oncology, 42(24), 2918-2927. https://doi.org/10.1200/jco.23.02736
Vancouver
Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW, Shergill A, et al. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of Clinical Oncology. 2024;42(24):2918-2927. doi:10.1200/jco.23.02736
BibTeX
@article{Kawazoe2024,
author = {Kawazoe, Akihito and Xu, Rui-Hua and García-Alfonso, Pilar and Passhak, Maria and Teng, Hao-Wei and Shergill, Ardaman and Gumus, Mahmut and Qvortrup, Camilla and Stintzing, Sebastian and Towns, Kathryn and Kim, Tae Won and Shiu, Kai Keen and Cundom, Juan and Ananda, Sumitra and Lebedinets, Andrey and Fu, Rong and Jain, Rishi and Adelberg, David and Heinemann, Volker and Yoshino, Takayuki and Elez, Elena and LEAP-017 Investigators, LEAP-017 Investigators},
title = {Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {24},
pages = {2918--2927},
doi = {10.1200/jco.23.02736}
}
EUVIMED